About us
Alevin Therapeutics is creating breakthrough approaches to safe and effective medicines for patients with life-threatening diseases.
We aim for therapeutic applications in fibrotic diseases with high unmet clinical need such as chronic kidney disease, acute kidney injury and ovarian cancer.
Our team has created a platform of novel small molecules targeting specific pathways within complex integrin biology. We aim to develop our preclinical and discovery-stage assets towards clinical application, to offer new treatments and relief for patients affected by life-limiting fibrotic conditions for which no effective therapies currently exist.
Our team has created a platform of novel small molecules targeting specific pathways within complex integrin biology. We aim to develop our preclinical and discovery-stage assets towards clinical application, to offer new treatments and relief for patients affected by life-limiting fibrotic conditions for which no effective therapies currently exist.
Company origins and development
Following decades of leadership in industrial and academic drug discovery, Alevin’s seasoned founding team leveraged the innovative research capabilities of the University of Nottingham (UoN) to create novel drug-like molecules targeting the integrin pathway.
Over a 10-year period, Alevin’s founders pursued an academic-industry collaboration, developing a new model of teaching for teaching undergraduate medicinal chemistry. This was subsequently extended into 4th Year undergraduate research projects resulting in mission-led academic invention of a diverse portfolio of patented integrin inhibitors and enabling know-how.
Over a 10-year period, Alevin’s founders pursued an academic-industry collaboration, developing a new model of teaching for teaching undergraduate medicinal chemistry. This was subsequently extended into 4th Year undergraduate research projects resulting in mission-led academic invention of a diverse portfolio of patented integrin inhibitors and enabling know-how.
Mill SciTech Park
Alevin was spun out of the University of Nottingham and incorporated March 2022, with ca. $1 M in pre-seed funding from the University and o2h Ventures. The IP is owned exclusively by Alevin Therapeutics, with patent (WO2022008918) filed, and progressed to national phase entry. The Company assets include a library of more than 600 novel, small molecule RGD-integrin inhibitors in several chemical series synthesized in the University, with robust, pharma-quality biological data (n = 2).
Alevin Therapeutics, headquartered at Mill SciTech Park near Cambridge, UK, was launched to develop this pipeline of integrin medicine innovation towards clinical use. With advanced preclinical assets and discovery capabilities to create additional programmes, Alevin is positioned to translate the fundamental research of UoN and our founders into new safe and effective therapies for fibrotic diseases.
Alevin Therapeutics, headquartered at Mill SciTech Park near Cambridge, UK, was launched to develop this pipeline of integrin medicine innovation towards clinical use. With advanced preclinical assets and discovery capabilities to create additional programmes, Alevin is positioned to translate the fundamental research of UoN and our founders into new safe and effective therapies for fibrotic diseases.